GlassScriptPhysician profile
Morgan Miller
NPI 1992156855
$2,204.41
in general payments reported to CMS, 2019-2025
25 companies · $42.40 in 2025
The $42.40 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.12 · 2020: $775 · 2021: $768 · 2022: $519 · 2023: $15.76 · 2024: $40.16 · 2025: $42.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $98.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $98.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $490.60 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $426.73 | 2020-2022 | |
| Abbvie INC. | $235.29 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $165.44 | 2020-2022 | |
| Amgen INC. | $117.87 | 2022-2024 | Tepezza |
| Allergan, INC. | $107.94 | 2020 | |
| Novo Nordisk INC | $93.17 | 2020-2022 | |
| Lilly USA, LLC | $86.66 | 2020-2022 | |
| Glaxosmithkline, LLC. | $61.66 | 2019-2021 | |
| Pfizer INC. | $53.51 | 2020-2021 | |
| Abbott Laboratories | $52.78 | 2022 | |
| Genentech USA, INC. | $50.17 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $42.40 | 2025 | Exparel |
| Astellas Pharma US INC | $30.08 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $23.60 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $21.31 | 2020 | |
| Medtronic, INC. | $20.08 | 2024 | Intellis Adaptivestim |
| Eisai INC. | $19.98 | 2020 | |
| Optinose US, INC. | $18.88 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.26 | 2022 | |
| Vanda Pharmaceuticals INC. | $17.12 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.68 | 2020 | |
| Radius Health, INC. | $13.00 | 2020 | |
| Dexcom, INC. | $12.63 | 2020 | |
| Amarin Pharma, INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.